Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | FOS | P01100 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12631824 | 0.82 | MEN1 (0.47) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL12631807 | 0.82 | HTT (0.34) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL12631795 | 0.82 | AKT1 (0.33) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL12631841 | 0.78 | KMT2A (0.43) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL11584085 | 0.78 | MEN1 (0.54) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL16414911 | 0.77 | MEN1 (0.43) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL16414912 | 0.77 | MEN1 (0.43) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL24096215 | 0.76 | ALDH1A1 (0.51) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL20875448 | 0.76 | SYK (0.57) | ALDH1A1TDP1POLBMEN1KMT2A | |
| SCHEMBL30392065 | 0.76 | ALDH1A1 (0.51) | ALDH1A1TDP1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947694-B2 | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | CDK1, CDK2, CDK4 | ALDH1A1 3158/4885TDP1 748/4885POLB 953/4885 |
| US-20080039477-A1 | Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors | CDK1, CDK2, CDKN1A | ALDH1A1 2526/4885TDP1 613/4885POLB 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.